A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $11 to $30
BioCryst Pharmaceuticals | 10-Q: Quarterly report
BioCryst Pharmaceuticals Is Maintained at Overweight by JP Morgan
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $13 to $20
BioCryst Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Express News | BioCryst Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $13 From $11
Express News | Needham Maintains Buy on BioCryst Pharma, Raises Price Target to $17
BioCryst Pharma Analyst Ratings
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
Top Midday Gainers
Earnings Call Summary | BioCryst Pharmaceuticals(BCRX.US) Q1 2025 Earnings Conference
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
$BCRX Stock Is up 14% Today. Here's What We See in Our Data.
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday
12 Health Care Stocks Moving In Monday's Pre-Market Session
BioCryst Rises on Strong Sales of Rare-Disease Drug
BioCryst Pharmaceuticals Reports Breakeven in Q1, Higher Revenue; Shares up Pre-Bell
BioCryst Pharmaceuticals | 8-K: BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
BioCryst Pharmaceuticals Pays Dn $75M of Debt; Saves $23.5M Over Life of Loan >BCRX
Express News | BioCryst Pharmaceuticals Inc: Expects to Be Profitable for Full Year 2025, a Year Ahead of Schedule